Imugene (IUGN.F) Stock Overview
A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IUGN.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Imugene Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.25 |
| 52 Week High | AU$1.44 |
| 52 Week Low | AU$0.061 |
| Beta | 2.61 |
| 1 Month Change | 14.55% |
| 3 Month Change | 20.92% |
| 1 Year Change | -69.37% |
| 3 Year Change | -94.11% |
| 5 Year Change | -92.59% |
| Change since IPO | 48.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| IUGN.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 24.4% | 4.4% | 2.9% |
| 1Y | -69.4% | 17.5% | 12.5% |
Return vs Industry: IUGN.F underperformed the US Biotechs industry which returned 17.4% over the past year.
Return vs Market: IUGN.F underperformed the US Market which returned 11.4% over the past year.
Price Volatility
| IUGN.F volatility | |
|---|---|
| IUGN.F Average Weekly Movement | 24.6% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: IUGN.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IUGN.F's weekly volatility has decreased from 36% to 25% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Leslie Chong | www.imugene.com |
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.
Imugene Limited Fundamentals Summary
| IUGN.F fundamental statistics | |
|---|---|
| Market cap | US$62.66m |
| Earnings (TTM) | -US$44.98m |
| Revenue (TTM) | US$2.87m |
Is IUGN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IUGN.F income statement (TTM) | |
|---|---|
| Revenue | AU$4.40m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$4.40m |
| Other Expenses | AU$73.42m |
| Earnings | -AU$69.02m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,569.81% |
| Debt/Equity Ratio | 20.5% |
How did IUGN.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/26 11:08 |
| End of Day Share Price | 2025/11/26 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Imugene Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Hunter Diamond | Diamond Equity Research LLC |
| Dennis Hulme | Edison Investment Research |